Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 297-300

  Cheng, Chien Yu ^a   Sheng, Wang Huei ^a   Wang, Jann Tay ^a   Chen, Yee Chun ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Colistin; Multidrug resistant Gram negative bacteria; Nephrotoxicity; Treatment outcomes

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; COLISTIMETHATE; LEVOFLOXACIN; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; AGED; APACHE; ARTICLE; BLOODSTREAM INFECTION; CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; GRAM NEGATIVE INFECTION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK BENEFIT ANALYSIS; TAIWAN; TREATMENT DURATION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 73549097280     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.11.016     Document Type: Article

References (16)

1. Leung C.H., Wang N.Y., Liu C.P., Weng L.C., Hsieh F.C., and Lee C.M. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan. J Microbiol Immunol Infect 41 (2008) 491-498
2. Shih M.J., Lee N.Y., Lee H.C., Chang C.M., Wu C.J., Chen P.L., et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. J Microbiol Immunol Infect 41 (2008) 118-123
3. Kallel H., Bahloul M., Hergafi L., Akrout M., Ketata W., Chelly H., et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28 (2006) 366-369
4. Reina R., Estenssoro E., Sáenz G., Canales H.S., Gonzalvo R., Vidal G., et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31 (2005) 1058-1065
5. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341
6. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988) 128-140
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth information supplement (2007), CLSI, Wayne, PA [Document M100-S17]
8. Evans M.E., Feola D.J., and Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 33 (1999) 960-967
9. Betrosian A.P., Frantzeskaki F., Xanthaki A., and Douzinas E.E. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56 (2008) 432-436
10. Furtado G.H., d'Azevedo P.A., Santos A.F., Gales A.C., Pignatari A.C., and Medeiros E.A. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 30 (2007) 315-319
11. Holloway K.P., Rouphael N.G., Wells J.B., King M.D., and Blumberg H.M. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 40 (2006) 1939-1945
12. Ouderkirk J.P., Nord J.A., Turett G.S., and Kislak J.W. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 47 (2003) 2659-2662
13. Oliveira M.S., Prado G.V., Costa S.F., Grinbaum R.S., and Levin A.S. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61 (2008) 1369-1375
14. Linden P.K., Kusne S., Coley K., Fontes P., Kramer D.J., and Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37 (2003) e154-e160
15. Falagas M.E., Fragoulis K.N., Kasiakou S.K., Sermaidis G.J., and Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26 (2005) 504-507
16. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., Barrero-Almodóvar A.E., García-Garmendia J.L., Bernabeu-Wittell M., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003) 1111-1118